Kunming Medical University, Kunming 650500, China; Department of Thoracic Tumor Surgery, Yunnan Cancer Center, Kunming 650118, China.
Department of Thoracic Tumor Surgery, Yunnan Cancer Center, Kunming 650118, China.
Biomed Pharmacother. 2021 May;137:111381. doi: 10.1016/j.biopha.2021.111381. Epub 2021 Feb 15.
With the continuous breakthroughs in molecular biology and biochemistry, we have constantly made great progress in the treatment of lung cancer. There is no doubt that standard treatment (such as surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy) has greatly improved the prognosis of lung cancer populations. In particular, the immunotherapy has brought more and more good news to countless lung cancer patients. In contrast to these standard treatments, traditional Chinese medicine (TCM) rarely has a profound and comprehensive overview in the field of lung cancer. This article will summarize the latest progress of TCM in lung cancer which is mainly non-small cell lung cancer (NSCLC) from theory to clinical practice, which would carry forward the sophisticated TCM and promote the development of modern medicine.
随着分子生物学和生物化学的不断突破，我们在肺癌的治疗方面不断取得重大进展。毫无疑问，标准治疗（如手术、放疗、化疗、靶向治疗和免疫治疗）极大地改善了肺癌人群的预后。特别是免疫治疗为无数肺癌患者带来了越来越多的好消息。与这些标准治疗相比，中医药在肺癌领域很少有深入和全面的概述。本文将从理论到临床实践，总结中医药治疗非小细胞肺癌（NSCLC）的最新进展，弘扬中医精髓，促进现代医学的发展。
